{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:42:13Z","timestamp":1792784533429,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"31","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Institute of Health","award":["AI-063356"],"award-info":[{"award-number":["AI-063356"]}]},{"name":"National Institute of Health","award":["AI-103960"],"award-info":[{"award-number":["AI-103960"]}]},{"name":"National Institute of Health","award":["HD-044864"],"award-info":[{"award-number":["HD-044864"]}]},{"name":"National Institute of Health","award":["HD-038416"],"award-info":[{"award-number":["HD-038416"]}]},{"name":"City of Hope cancer center core services award","award":["P30CA033572"],"award-info":[{"award-number":["P30CA033572"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.vaccine.2014.05.011","type":"journal-article","created":{"date-parts":[[2014,5,20]],"date-time":"2014-05-20T19:15:27Z","timestamp":1400613327000},"page":"3963-3970","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Development of a novel, guinea pig-specific IFN-\u03b3 ELISPOT assay and characterization of guinea pig cytomegalovirus GP83-specific cellular immune responses following immunization with a modified vaccinia virus Ankara (MVA)-vectored GP83 vaccine"],"prefix":"10.1016","volume":"32","author":[{"given":"Peter A.","family":"Gillis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelmary","family":"Hernandez-Alvarado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine S.","family":"Gnanandarajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Wussow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don J.","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Schleiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2014.05.011_bib0005","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.2174\/138945011795677827","article-title":"Guinea pig model of infectious disease \u2013 viral infections","volume":"12","author":"Hickey","year":"2011","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0010","first-page":"324","article-title":"The guinea pig as a model of infectious diseases","volume":"58","author":"Padilla-Carlin","year":"2008","journal-title":"Comp Med"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0015","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.copbio.2012.03.007","article-title":"Recombinant live vaccine candidates against tuberculosis","volume":"23","author":"Kaufmann","year":"2012","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0020","first-page":"8","article-title":"Vaccination with recombinant mycobacterium tuberculosis PknD attenuates bacterial dissemination to the brain in guinea pigs","author":"Skerry","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0025","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1016\/j.vaccine.2010.12.057","article-title":"A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle","volume":"29","author":"Lin","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0030","doi-asserted-by":"crossref","first-page":"6357","DOI":"10.1128\/JVI.00019-09","article-title":"Development of infectious clones for virulent and avirulent pichinde viruses: a model virus to study arenavirus-induced hemorrhagic fevers","volume":"83","author":"Lan","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0035","doi-asserted-by":"crossref","first-page":"6635","DOI":"10.1128\/JVI.00044-13","article-title":"Identification of virulence determinants within the L genomic segment of the pichinde arenavirus","volume":"87","author":"McLay","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0040","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1016\/j.vaccine.2013.04.078","article-title":"Effects of immunization of pregnant guinea pigs with guinea pig cytomegalovirus glycoprotein B on viral spread in the placenta","volume":"31","author":"Hashimoto","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0045","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1016\/j.vaccine.2009.04.036","article-title":"A live guinea pig cytomegalovirus vaccine deleted of three putative immune evasion genes is highly attenuated but remains immunogenic in a vaccine\/challenge model of congenital cytomegalovirus infection","volume":"27","author":"Crumpler","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0050","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/infdis\/138.2.197","article-title":"Cytomegalovirus-infection in guinea-pigs. 2. Transplacental and horizontal transmission","volume":"138","author":"Choi","year":"1978","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0055","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1089\/vim.2000.13.155","article-title":"Immunogenicity evaluation of DNA vaccines that target guinea pig cytomegalovirus proteins glycoprotein B and UL83","volume":"13","author":"Schleiss","year":"2000","journal-title":"Viral Immunol"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0060","first-page":"8","article-title":"Intravaginal cytomegalovirus (CMV) challenge elicits maternal viremia results in congenital transmission in a guinea pig model","author":"Olejniczak","year":"2011","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0065","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1002\/j.1460-2075.1986.tb04606.x","article-title":"Identification of the human cytomegalovirus glycoprotein-B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus","volume":"5","author":"Cranage","year":"1986","journal-title":"EMBO J"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0070","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1086\/382751","article-title":"Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine","volume":"189","author":"Schleiss","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0075","doi-asserted-by":"crossref","first-page":"7569","DOI":"10.1128\/JVI.70.11.7569-7579.1996","article-title":"The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL","volume":"70","author":"Wills","year":"1996","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0080","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1086\/511982","article-title":"Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection","volume":"195","author":"Schleiss","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0085","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0165-2478(98)00080-7","article-title":"Cytomegalovirus-specific IFN gamma and IL-4 are produced by antigen expanded human blood lymphocytes from seropositive volunteers","volume":"64","author":"Kallas","year":"1998","journal-title":"Immunol Lett"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0090","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1399-3062.2009.00446.x","article-title":"Kinetics of interferon-gamma producing cytomegalovirus (CMV)-specific CD4+and CD8+T lymphocytes and the risk of subsequent CMV viremia after allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Eid","year":"2009","journal-title":"Transpl Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2014.05.011_bib0095","first-page":"CD005129","article-title":"Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients","author":"Hodson","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0100","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1086\/508997","article-title":"Protective immunity to cytomegalovirus (CMV) retinitis in AIDS is associated with CMV-specific T cells that express interferon-G and interleukin-2 and have a CD8(+) cell early maturational phenotype","volume":"194","author":"Sinclair","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0105","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1089\/vim.2006.19.220","article-title":"Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response","volume":"19","author":"Bettahi","year":"2006","journal-title":"Viral Immunol"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0110","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.vetimm.2004.01.004","article-title":"Vaccine-induced T cell-mediated immunity plays a critical role in early protection against pseudorabies virus (suid herpes virus type 1) infection in pigs","volume":"99","author":"van Rooij","year":"2004","journal-title":"Vet Immunol Immunopathol"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0115","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1128\/JVI.01708-06","article-title":"Immunogenicity and protective efficacy of DNA vaccines expressing rhesus cytomegalovirus glycoprotein B, phosphoprotein 65-2, and viral interleukin-10 in rhesus macaques","volume":"81","author":"Yue","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0120","doi-asserted-by":"crossref","first-page":"7766","DOI":"10.1128\/JVI.00633-07","article-title":"DNA immunization using highly conserved murine cytomegalovirus genes encoding homologs of human cytomegalovirus UL54 (DNA polymerase) and UL105 (helicase) elicits strong CD8 T-cell responses and is protective against systemic challenge","volume":"81","author":"Morello","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0125","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.4049\/jimmunol.172.4.2256","article-title":"Human cytomegalovirus proteins pp65 and immediate early protein 1 are common targets for CD8(+) T cell responses in children with congenital or postnatal human cytomegalovirus infection","volume":"172","author":"Gibson","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0130","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1086\/339963","article-title":"Comparative analysis of CD8(+) T cell responses against human cytomegalovirus proteins pp65 and immediate early 1 shows similarities in precursor frequency, oligoclonality, and phenotype","volume":"185","author":"Khan","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0135","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1515\/BC.2008.065","article-title":"Analysis of the human cytomegalovirus pp65-directed T-cell response in healthy HLA-A2-positive individuals","volume":"389","author":"Schalich","year":"2008","journal-title":"Biol Chem"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0140","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jim.2007.08.012","article-title":"Monoclonal antibodies to guinea pig interferon-gamma: tools for cytokine detection and neutralization","volume":"328","author":"Sch\u00e4fer","year":"2007","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0145","doi-asserted-by":"crossref","first-page":"5804","DOI":"10.1016\/j.vaccine.2012.07.012","article-title":"Tools for cellular immunology and vaccine research the in the guinea pig: monoclonal antibodies to cell surface antigens and cell lines","volume":"30","author":"Sch\u00e4fer","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0150","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1128\/IAI.71.1.354-364.2003","article-title":"Differential expression of gamma interferon mRNA induced by attenuated and virulent Mycobacterium tuberculosis in guinea pig cells after Mycobacterium bovis BCG vaccination","volume":"71","author":"Jeevan","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0155","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.vaccine.2006.09.067","article-title":"Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1","volume":"25","author":"Wang","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0160","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1182\/blood-2003-10-3469","article-title":"Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells","volume":"104","author":"Wang","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0165","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1128\/JVI.78.8.3965-3976.2004","article-title":"Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus","volume":"78","author":"Wang","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0170","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1006\/viro.1994.1333","article-title":"Cloning and characterization of the guinea-pig cytomegalovirus glycoprotein-B gene","volume":"202","author":"Schleiss","year":"1994","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0175","doi-asserted-by":"crossref","first-page":"7979","DOI":"10.1016\/j.vaccine.2010.09.061","article-title":"Temporal changes in the gene signatures of BCG-vaccinated guinea pigs in response to different mycobacterial antigens","volume":"28","author":"Tree","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0180","first-page":"8","article-title":"Immunity of foot-and-mouth disease serotype asia 1 by sublingual vaccination","author":"Chen","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0185","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.antiviral.2012.09.019","article-title":"Development of foot-and-mouth disease virus (FMDV) serotype O virus-like-particles (VLPs) vaccine and evaluation of its potency","volume":"96","author":"Mohana Subramanian","year":"2012","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0190","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1146\/annurev-pathol-020712-164041","article-title":"Pathogenesis of the viral hemorrhagic fevers","volume":"8","author":"Paessler","year":"2013","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0195","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jcv.2007.10.008","article-title":"Comparison of vaccine strategies against congenital CMV infection in the guinea pig model","volume":"41","author":"Schleiss","year":"2008","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0200","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/(SICI)1096-9071(199606)49:2<124::AID-JMV9>3.0.CO;2-7","article-title":"cell immunity to human cytomegalovirus glycoprotein B","volume":"49","author":"Hopkins","year":"1996","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0205","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1084\/jem.168.3.919","article-title":"Human cytomegalovirus-specific cytotoxic T cells relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses","volume":"168","author":"Borysiewicz","year":"1988","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0210","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM199510193331603","article-title":"Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor","volume":"333","author":"Walter","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0215","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1128\/IAI.74.1.213-224.2006","article-title":"Production and characterization of guinea pig recombinant gamma interferon and its effect on macrophage activation","volume":"74","author":"Jeevan","year":"2006","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0220","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1128\/JVI.70.4.2162-2169.1996","article-title":"Anti-human cytomegalovirus activity of cytokines produced by CD4+ T-cell clones specifically activated by IE1 peptides in vitro","volume":"70","author":"Davignon","year":"1996","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0225","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.4049\/jimmunol.179.6.4283","article-title":"Massive load of functional effector CD4+ and CD8+ T cells against cytomegalovirus in very old subjects","volume":"179","author":"Vescovini","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0230","doi-asserted-by":"crossref","first-page":"6465","DOI":"10.1182\/blood-2009-02-203307","article-title":"Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients","volume":"113","author":"Zhou","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0235","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/ajt.12049","article-title":"Pretransplant interferon- secretion by CMV-specific CD8+T cells informs the risk of CMV replication after transplantation","volume":"13","author":"Cantisan","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0240","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1099\/vir.0.81516-0","article-title":"Characterization and immunological analysis of the rhesus cytomegalovirus homologue (Rh112) of the human cytomegalovirus UL83 lower matrix phosphoprotein (pp65)","volume":"87","author":"Yue","year":"2006","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0245","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.1128\/JVI.77.9.5226-5240.2003","article-title":"Ex vivo profiling of CD8(+)-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers","volume":"77","author":"Elkington","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0250","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1084\/jem.20050882","article-title":"Broadly targeted human cytomegalovirus-specific CD4(+) and CD8(+) T cells dominate the memory compartments of exposed subjects","volume":"202","author":"Sylwester","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0255","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0165-2478(02)00073-1","article-title":"Identification of HLA-A24-restricted CTL epitope encoded by the matrix protein pp65 of human cytomegalovirus","volume":"83","author":"Akiyama","year":"2002","journal-title":"Immunol Lett"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0260","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1365-2141.2005.05800.x","volume":"131","author":"Ohnishi","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0265","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1128\/JVI.75.5.2472-2474.2001","article-title":"Infrequent occurrence of natural mutations in the pp65(495\u2013503) epitope sequence presented by the HLA A*0201 allele among human cytomegalovirus isolates","volume":"75","author":"Zaia","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0270","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/00002371-200207000-00006","article-title":"Identification of immune dominant cytomegalovirus epitopes using quantitative real-time polymerase chain reactions to measure interferon-gamma production by peptide-stimulated peripheral blood mononuclear cells","volume":"25","author":"Provenzano","year":"2002","journal-title":"J Immunother"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0275","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jim.2005.02.004","article-title":"Identification of T cell epitopes by the use of rapidly generated mRNA fragments","volume":"299","author":"Britten","year":"2005","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2014.05.011_bib0280","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/350703a0","article-title":"Peptide selection by MHC class I molecules","volume":"350","author":"Schumacher","year":"1991","journal-title":"Nature"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14006677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14006677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T13:52:15Z","timestamp":1597845135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14006677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":56,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0264410X14006677"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.05.011","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a novel, guinea pig-specific IFN-\u03b3 ELISPOT assay and characterization of guinea pig cytomegalovirus GP83-specific cellular immune responses following immunization with a modified vaccinia virus Ankara (MVA)-vectored GP83 vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}